Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

MD DIAGNOSTICS LLC

NPI: 1285201343 · SAINT LOUIS, MO 63123 · Clinical Medical Laboratory · NPI assigned 06/08/2021

$75K
Total Medicaid Paid
3,489
Total Claims
2,756
Beneficiary Records
21
Codes Billed
2023-10
First Month
2024-06
Last Month

Provider Details

Authorized OfficialHAYAT, SYED (OWNER)
NPI Enumeration Date06/08/2021

Related Entities

Other providers sharing the same authorized official: HAYAT, SYED

ProviderCityStateTotal Paid
FAMILY WELLNESS PROGRAM, LLC BRONX NY $320.01M
SIMPSON SOLUTIONS, LLC MOUNT VERNON NY $9.29M

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2023 1,706 $25K
2024 1,783 $50K

Billing Codes

CodeDescriptionClaimsBene. RecordsTotal Paid
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 507 363 $24K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 617 444 $16K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 173 144 $15K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 34 34 $6K
84443 Thyroid stimulating hormone (TSH) 238 215 $2K
80061 Lipid panel 325 270 $2K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 140 117 $2K
80053 Comprehensive metabolic panel 337 281 $2K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 423 314 $2K
83036 Hemoglobin; glycosylated (A1C) 331 276 $2K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 23 21 $775.74
87581 23 21 $589.47
84153 40 37 $500.14
87631 23 21 $228.20
84436 49 44 $208.62
80299 24 24 $164.01
82607 22 14 $108.54
84439 23 19 $108.15
81001 40 30 $45.54
87086 Culture, bacterial; quantitative colony count, urine 18 12 $32.25
36415 Collection of venous blood by venipuncture 79 55 $0.00